Sign In
Buy BAYRY
$13.89
-0.110 (-0.786%)
At Close: Jul 31, 2026
Bayer extends contract of CEO until March 2029
10:39am, Wednesday, 16'th Jul 2025
Germany's Bayer said on Wednesday that its supervisory board had extended the contract of CEO Bill Anderson until March 31, 2029.
BAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?
09:26am, Wednesday, 16'th Jul 2025
Bayer's shares are up 62.9% YTD as new drug approvals and a streamlined model fuel a sharp pharma turnaround.
Bayer: Upside Compelling - Buy
07:46am, Wednesday, 16'th Jul 2025
Bayer is a deep contrarian play, trading at less than 6x P/E, with potential for 100%+ upside if litigation risks subside. The main risks are ongoing glyphosate litigation and pharma pricing pressures
Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart Failure
10:36am, Monday, 14'th Jul 2025
BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major conditions.
Bayer Wins Hormone-Free Treatment Approval for Women in the UK
11:11am, Friday, 11'th Jul 2025
BAYRY secures first global approval for Lynkuet in the UK, a hormone-free treatment for menopause-related hot flashes.
Best Value Stocks to Buy for July 10th
08:56am, Thursday, 10'th Jul 2025
BAYRY, INSW and GOOS made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 10, 2025.
New Strong Buy Stocks for July 10th
06:35am, Thursday, 10'th Jul 2025
ASTH, LGCY, STM, BAYRY and KD have been added to the Zacks Rank #1 (Strong Buy) List on July 10, 2025.
Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy
07:07am, Wednesday, 09'th Jul 2025
The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy are eased by an experimental non-hormonal drug being developed by Bayer , according t
Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease
11:36am, Tuesday, 08'th Jul 2025
BAYRY begins human trials for OpCT-001, an experimental cell therapy for treating primary photoreceptor diseases.
What Makes Bayer (BAYRY) a New Buy Stock
01:00pm, Thursday, 03'rd Jul 2025
Bayer (BAYRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bayer Appoints Priyal Patel as Chief Financial Officer for North America
08:59am, Tuesday, 01'st Jul 2025
ST. LOUIS--(BUSINESS WIRE)--Bayer today announced the appointment of Priyal Patel as Cluster Chief Financial Officer (CFO) for North America, effective July 1, 2025. In her new role, Patel will overse
US Supreme Court seeks Justice Department views on Bayer's Roundup appeal
10:07am, Monday, 30'th Jun 2025
The U.S. Supreme Court asked President Donald Trump's administration on Monday for its views on Bayer's bid to sharply limit lawsuits claiming that the company's Roundup weedkiller causes cancer and p
Bayer says U.S. Supreme Court asks solicitor general for opinion in glyphosate case
09:52am, Monday, 30'th Jun 2025
Bayer said on Monday that the U.S. Supreme Court had asked the solicitor general for an opinion in the Durnell case, as the German company seeks clarity from the top U.S. court in litigation related t
Court Approves $38M Cash Settlement Against Bayer AG in Hard-Fought Securities Class Action
03:51pm, Friday, 27'th Jun 2025
Following the Bayer-Monsanto merger, litigation has resulted in a valuable settlement that, pending final approval, affirms the rights of ADR investors to
Bayer share price is rising: does it have more upside?
02:04am, Thursday, 26'th Jun 2025
Bayer share price has bounced back this year, making it one of the best-performing companies in the German DAX Index. It has jumped to €26, up by 45% from its lowest point this year.
